{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:57:08Z","timestamp":1791341828387,"version":"4.3.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"am","delay-in-days":310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R41DA053081"],"award-info":[{"award-number":["R41DA053081"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K01AA024796"],"award-info":[{"award-number":["K01AA024796"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jsat.2022.108896","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T11:13:01Z","timestamp":1664881981000},"page":"108896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic"],"prefix":"10.1016","volume":"143","author":[{"given":"Kevin A.","family":"Hallgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Darnton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Soth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Blalock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Michaels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Grekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Woolworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108896_bb0005","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2021"},{"issue":"108552","key":"10.1016\/j.jsat.2022.108896_bb0010","first-page":"1","article-title":"Changes in methadone take-home dosing before and after COVID-19","volume":"113","author":"Amram","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0015","article-title":"Characterizing the clinical use of a novel video-assisted dosing protocol with secure medication dispensers to reduce barriers to opioid treatment","author":"Brooklyn","year":"2021","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2022.108896_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19","volume":"131","author":"Brothers","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108197","article-title":"Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic","volume":"121","author":"Dunn","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0030","series-title":"42 CFR \u00a7 8.12","year":"2015"},{"key":"10.1016\/j.jsat.2022.108896_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like 'liquid handcuffs\u201d: The effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2022.108896_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ADM.0000000000000608","article-title":"Acceptability and feasibility of a Mobile health application for video directly observed therapy of buprenorphine for opioid use disorders in an office-based setting","volume":"14","author":"Godersky","year":"2020","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2022.108896_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence","volume":"14","author":"Godersky","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2022.108896_bb0050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jama.2022.1271","article-title":"Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation","volume":"327","author":"Gomes","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108896_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108223","article-title":"Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives","volume":"124","author":"Hatch-Maillette","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108786","article-title":"Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder","volume":"225","author":"Holtyn","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108896_bb0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse clinical trials network task force report","volume":"42","author":"Joudrey","year":"2021","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2022.108896_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108328","article-title":"Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic","volume":"126","author":"Kidorf","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109100","article-title":"Treatment provider perceptions of take-home methadone regulation before and during COVID-19","volume":"228","author":"Madden","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108896_bb0080","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review","volume":"372","author":"Mathers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2022.108896_bb0085","series-title":"Overdose death rates [WWW document]","year":"2021"},{"key":"10.1016\/j.jsat.2022.108896_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2022.108896_bb0095","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s10461-020-02887-1","article-title":"Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program","volume":"24","author":"Peavy","year":"2020","journal-title":"AIDS and Behavior"},{"key":"10.1016\/j.jsat.2022.108896_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108375","article-title":"Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs","volume":"129","author":"Poorman","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108896_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-020-00203-9","article-title":"Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: Protocol for a pilot randomized controlled trial","volume":"15","author":"Schramm","year":"2020","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2022.108896_bb0110","article-title":"Emergency Department Visits for nonfatal opioid overdose during the COVID-19 pandemic across six US Health Care Systems","author":"Soares","year":"2021","journal-title":"Annals of Emergency Medicine"},{"key":"10.1016\/j.jsat.2022.108896_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102696","article-title":"Trajectories of retention in opioid agonist therapy in a Canadian setting","volume":"77","author":"Soc\u00edas","year":"2020","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2022.108896_bb0120","series-title":"Opioid Treatment Program (OTP) guidance","year":"2020"},{"key":"10.1016\/j.jsat.2022.108896_bb0125","series-title":"Opioid treatment program directory","year":"2022"},{"key":"10.1016\/j.jsat.2022.108896_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108917","article-title":"Video directly observed therapy for patients receiving office-based buprenorphine \u2013 a pilot randomized controlled trial","volume":"227","author":"Tsui","year":"2021","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:57:56Z","timestamp":1760039876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"alternative-id":["S0740547222001787"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108896","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108896"}}